Research graph
References from Organ preservation in rectal cancer – Challenges and future strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy
10.1016/0360-3016(83)90384-x · 1983 · External reference
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(15)00159-x · 2015 · External reference
The 'Holy Plane' of rectal surgery
10.1177/014107688808100904 · 1988 · External reference
Local control and survival after extralevator abdominoperineal excision for locally advanced or low rectal cancer
10.1111/codi.12610 · 2014 · External reference
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203
10.1200/jco.2006.06.7629 · 2006 · External reference
Preoperative versus postoperative chemoradiotherapy for rectal cancer
10.1056/nejmoa040694 · 2004 · External reference
Functional results after radiochemotherapy and total mesorectal excision for rectal cancer
10.1007/s00384-007-0276-0 · 2007 · External reference
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer
10.1200/jco.2011.37.7176 · 2011 · External reference
Unresolved reference
External reference
Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation-interim analysis of the German OCUM Trial (NCT01325649)
10.1007/s11605-015-3011-0 · 2016 · External reference
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results
10.1097/01.sla.0000141194.27992.32 · 2004 · External reference
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy
10.1016/j.gassur.2006.09.005 · 2006 · External reference
Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer
10.1093/jnci/djw171 · 2016 · External reference
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study
2015 · External reference
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
2015 · External reference
Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial
10.1200/jco.1999.17.8.2396 · 1999 · External reference
An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer
10.1245/s10434-008-9892-3 · 2008 · External reference
Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer
10.1097/sla.0b013e3181b91e63 · 2009 · External reference
Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)
10.1200/jco.2016.67.6049 · 2016 · External reference
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
10.1002/bjs.9112 · 2013 · External reference
Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: A meta-analysis of published studies
10.1097/sla.0000000000000368 · 2016 · External reference
Results of a prospective randomised control 6 vs 12 trial: is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?
10.1093/annonc/mdw370.01 · 2016 · External reference
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial
10.1016/j.ijrobp.2014.07.021 · 2014 · External reference
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
10.1016/s1470-2045(15)00004-2 · 2015 · External reference
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
10.1200/jco.2011.36.4539 · 2011 · External reference
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(15)00159-x · 2015 · External reference
Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis
10.1016/j.ejca.2012.09.026 · 2013 · External reference
Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: an updated systematic review and meta-analysis
10.18632/oncotarget.9995 · 2016 · External reference
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04
10.1200/jco.2013.53.7753 · 2014 · External reference
Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial
10.1093/jnci/djv248 · 2015 · External reference
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial
10.1200/jco.2010.34.4911 · 2011 · External reference
Final results of STAR-01: a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer
10.1200/jco.2016.34.15_suppl.3521 · 2016 · External reference
Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial
10.1200/jco.2016.66.6198 · 2016 · External reference
Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study
2015 · External reference
ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: results after 5 years of follow-up
10.1200/jco.2016.34.4_suppl.490 · 2016 · External reference
PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis
10.1016/s0959-8049(14)70023-1 · 2014 · External reference
Targeted agents in GI radiotherapy: clinical efficacy and side effects
10.1016/j.bpg.2016.05.002 · 2016 · External reference
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer
10.1016/j.ijrobp.2013.02.020 · 2013 · External reference
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)
10.1200/jco.2011.39.6036 · 2012 · External reference
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
10.1186/s12885-015-1053-z · 2015 · External reference
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
10.1016/j.ijrobp.2009.02.037 · 2010 · External reference
Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer
2009 · External reference
Stellenwert der Hyperthermie für die chirurgische Onkologie
10.1055/s-2002-36060 · 2002 · External reference
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
10.3109/02656736.2012.722263 · 2012 · External reference
Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer
10.3109/02656736.2015.1117661 · 2016 · External reference
Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
10.3109/02656730903333958 · 2010 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy
10.1016/j.ijrobp.2012.05.017 · 2013 · External reference
Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis
10.1016/j.radonc.2014.08.035 · 2014 · External reference
Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography
10.1186/s13014-014-0311-6 · 2015 · External reference
Biological Image-Guided Radiotherapy in Rectal Cancer: Challenges and Pitfalls
10.1016/j.ijrobp.2008.11.031 · 2009 · External reference
Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice
10.1007/s00066-015-0913-4 · 2016 · External reference
The MRI-Linear Accelerator Consortium: evidence-based clinical introduction of an innovation in radiation oncology connecting researchers, methodology, data collection, quality assurance, and technical development
10.3389/fonc.2016.00215 · 2016 · External reference
The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review
10.1016/j.radonc.2014.11.026 · 2014 · External reference
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization
10.1007/dcr.0b013e3181f42b89 · 2010 · External reference
Clinical significance of the endoscopic finding in predicting complete tumor response to preoperative chemoradiation therapy in rectal cancer
10.1007/s00268-016-3661-4 · 2016 · External reference
Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis
10.1148/radiol.13122833 · 2013 · External reference
10.1007/s003840050072 · 1997 · Admitted local publication
Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience
10.1200/jco.2011.34.9068 · 2011 · External reference
Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy
10.1097/dcr.0000000000000667 · 2016 · External reference
The role of diffusion-weighted MRI and 18 F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review
10.1016/j.radonc.2014.11.026 · 2014 · External reference
Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: a multicentric prospective study with external validation
10.1016/j.radonc.2014.11.002 · 2014 · External reference
Radiomics: extracting more information from medical images using advanced feature analysis
10.1016/j.ejca.2011.11.036 · 2012 · External reference
External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma
10.3109/0284186x.2015.1061214 · 2015 · External reference
Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience
10.1007/s00261-016-0733-8 · 2016 · External reference
Rectal cancer: assessment of neoadjuvant chemo-radiation outcome based on radiomics of multi-parametric MRI
2016 · External reference
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer
10.1016/j.ijrobp.2009.03.003 · 2009 · External reference
The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis
10.1016/j.radonc.2004.12.021 · 2005 · External reference
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma
10.1200/jco.2010.32.3212 · 2011 · External reference
Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival
10.1158/1078-0432.ccr-10-2592 · 2011 · External reference
KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy
10.1245/s10434-016-5205-4 · 2016 · External reference
GammaH2AX and cancer
10.1038/nrc2523 · 2008 · External reference
Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody
10.1667/0033-7587(2002)158[0486:qdoiid]2.0.co;2 · 2002 · External reference
Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair
10.1016/j.molcel.2005.10.003 · 2005 · External reference
A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery
10.1038/nature04384 · 2006 · External reference
GammaH2AX as a checkpoint maintenance signal
10.4161/cc.5.13.2899 · 2006 · External reference
PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint
10.1038/embor.2008.162 · 2008 · External reference
Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays
10.1016/j.radonc.2006.07.026 · 2006 · External reference
Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining
10.3109/09553000903242149 · 2009 · External reference
Residual gammaH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness
10.1016/j.radonc.2015.08.006 · 2015 · External reference
Circulating tumor cells and circulating tumor DNA
10.1146/annurev-med-062310-094219 · 2012 · External reference
Cell-free nucleic acids as biomarkers in cancer patients
10.1038/nrc3066 · 2011 · External reference
Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy
10.1245/s10434-011-1638-y · 2011 · External reference
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
10.18632/oncotarget.5256 · 2015 · External reference
